Australian biotech market watch 02/10/09
Friday, 02 October, 2009
The All Ordinaries has followed the Dow Jones and other international indices by dropping nearly 2% in today's trading on the back of fears of continued economic strife in the United States. The health index managed to keep the slide to a minimum, shedding only 0.7%.
At the forefront of the losses was Biota Holdings (ASX:BTA), which receives royalties for the anti-viral drug, Relenza, which dropped 2.8% to $2.77.
Ramsay Health Care (ASX:RHC) also lost 2% of its value, down to $10.86, bringing it back to its Monday start after peaking at $11.10 mid-week.
Medical implant company, Cochlear (ASX:COH) saw a $1.15 dip to $66.42, and CSL (ASX:CSL) slipped 22c to $33.22.
It wasn't all bad news though. Blackmores (ASX:BKL) nudged upwards half a per cent to $20.23, after having a shaky start this morning.
Photoprotective drug company, Clinuvel (ASX:CUV) also saw a late jump of over 10% to $0.38, putting its stock at a four month high.
Next-gen therapies could treat high-grade gliomas
Government funding will enable researchers to test a suite of next-generation therapies they have...
Bacteriophage cocktail to combat superbugs
Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...
Exclusive colostrum intake may reduce risk of food allergies
Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...
